Terzano Mario Giovanni, Parrino Liborio, Spaggiari Maria Cristina, Palomba Vincenzo, Rossi Mariano, Smerieri Arianna
Sleep Disorders Center, Department of Neurology, University of Parma, Via del Quartiere, 4, 43100 Parma, Italy.
Clin Neurophysiol. 2003 Sep;114(9):1715-23. doi: 10.1016/s1388-2457(03)00136-6.
Polysomnographic (PSG) measures consistently reflect poor sleep quality and effective treatment in insomniac patients.
The PSG findings of 47 patients (18 M and 29 F, 42.5+/-10 years) meeting the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for a diagnosis of primary insomnia were compared with those of 25 age- and gender-balanced healthy subjects (controls) without sleep complaints. After one adaptation night to the sleep lab, each patient underwent two randomized double-blind PSG recordings. Twenty-four patients followed a placebo-drug sequence and 23 a drug-placebo succession. Active treatment consisted of widely used hypnotic drugs, i.e. zolpidem, triazolam, zopiclone, brotizolam. Conventional PSG measures, electroencephalogram (EEG) arousals and CAP variables (including phase A subtypes) were quantified and statistically analyzed.
Compared to controls, insomniac patients under placebo showed a significant increase of CAP rate, subtypes A1 and A2, EEG arousals, nocturnal wakefulness and stage 1, associated with reduced values of total sleep time and slow wave sleep (stages 3 and 4). In insomniac patients, sleep quality was significantly improved by hypnotic treatment. Compared to placebo, active medication significantly reduced CAP rate, subtypes A1 and A2, but had only marginal effects on subtypes A3 and on EEG arousals. Under hypnotic treatment total sleep time, nocturnal awakenings, stage 1 and slow wave sleep recuperated normal values. The most significant correlation between sleep quality and PSG variables was found for CAP rate (P<0.0001).
PSG investigation extended to CAP variables and EEG arousals can be an important procedure for the diagnosis of primary insomnia and evaluation of treatment efficacy.
多导睡眠图(PSG)测量结果始终能反映失眠患者睡眠质量差及有效治疗情况。
将47例符合《精神障碍诊断与统计手册》第四版原发性失眠诊断标准的患者(18例男性和29例女性,年龄42.5±10岁)的PSG结果与25例无睡眠主诉、年龄和性别均衡的健康受试者(对照组)进行比较。在适应睡眠实验室一个晚上后,每位患者接受两次随机双盲PSG记录。24例患者采用安慰剂 - 药物顺序,23例采用药物 - 安慰剂顺序。积极治疗采用广泛使用的催眠药物,即唑吡坦、三唑仑、佐匹克隆、溴替唑仑。对常规PSG测量、脑电图(EEG)觉醒和CAP变量(包括A期亚型)进行量化和统计分析。
与对照组相比,服用安慰剂的失眠患者CAP率、A1和A2亚型、EEG觉醒、夜间觉醒和1期睡眠显著增加,同时总睡眠时间和慢波睡眠(3期和4期)值降低。在失眠患者中,催眠治疗显著改善了睡眠质量。与安慰剂相比,积极用药显著降低了CAP率、A1和A2亚型,但对A3亚型和EEG觉醒仅有轻微影响。在催眠治疗下,总睡眠时间、夜间觉醒、1期睡眠和慢波睡眠恢复到正常值。发现睡眠质量与PSG变量之间最显著的相关性为CAP率(P<0.0001)。
扩展至CAP变量和EEG觉醒的PSG检查可成为原发性失眠诊断和治疗效果评估的重要手段。